The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

The U.S. health agency, the Centers for Medicare & Medicaid Services (CMS), announced Tuesday that it will appeal a November 2024 ruling to the Fifth Circuit Court of Appeals. What Happened: In October,

The CMS said 24.2 million people signed up during the enrollment window, including 3.9 million new enrollees. That's more than double the number of people who enrolled during the 2021 sign-up period, according to the announcement.

The feds intend to appeal a judge's decision that would force them to recalculate UnitedHealthcare's Medicare Advantage (MA) star ratings. | The feds intend to appeal a judge's decision that would force them to recalculate UnitedHealthcare's Medicare Advantage star ratings.

The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started, so current drug prices are unaffected.

Federal health agencies, including the Centers for Medicare & Medicaid Services, have halted their communication efforts in the first days of the Trump administration.

In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan year.

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations for 2026, the new prices achieved an average of 22% savings.

Final rule makes it easier for CMS to suspend agents and brokers who exchange plans without notifying the Medicare customer.

Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.

Providers are required by federal law to return Medicare and Medicaid overpayments within 60 days of identifying the overpayment or they can be